Author:
Zhao Qinqin,Zheng Bei,Han Bing,Feng Pinpin,Xia Zhongni,Jiang Hong,Ying Yin,Zhu Jun,Fei Cheng,Xiang Junlei,Shen Lingli,Luo Qiliang,Wu Yinhuan,Wusiman Ayiguzhali,Xin Chuanwei,Zhang Meiling,Li Gonghua,Li Xiang
Funder
National Natural Science Foundation of China
Medical Science and Technology Project of Zhejiang Province
Zhejiang Pharmaceutical Association
Publisher
Springer Science and Business Media LLC
Subject
Infectious Diseases,Microbiology (medical)
Reference31 articles.
1. Barber RM, Sorensen RJD, Pigott DM, et al. Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis. Lancet. 2022;399(10344):2351–80. https://doi.org/10.1016/s0140-6736(22)00484-6.
2. Cao YL, Wang J, Jian FC, et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature. 2022;602(7898):657–63. https://doi.org/10.1038/s41586-021-04385-3.
3. Viana R, Moyo S, Amoako DG, et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature. 2022;603(7902):679–86. https://doi.org/10.1038/s41586-022-04411-y.
4. Rahmah L, Abarikwu SO, Arero AG, et al. Oral antiviral treatments for COVID-19: opportunities and challenges. Pharmacol Rep. 2022;74(6):1255–78. https://doi.org/10.1007/s43440-022-00388-7.
5. National Medical Products Administration. NMPA conditionally approved the import registration of Pfizer's novel coronavirus treatment Nematavir tablet/Ritonavir tablet combination package. 2022. https://www.nmpa.gov.cn/yaowen/ypjgyw/20220212085753142.html. Accessed Apr 22, 2023.
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献